Mukka Proteins raises ₹47 cr via warrants, buys two fish meal firms for ₹26 cr
The micro-cap protein player is tackling liquidity stress flagged by a recent credit downgrade while expanding core production capacity via two acquisitions.
— 3 earlier stories on Mukka Proteins Ltd. →What's new
- Board approved preferential allotment of 2 cr warrants at ₹23.50 each to 15 non-promoter investors, raising ₹47 crore.
- Board cleared acquisition of 51% in Delta Marine for ₹11.1 cr and 51% in Aqua Marine for ₹15 cr.
- Delta Marine had a loss of ₹19.7 lakh on revenue of ₹28.2 cr in FY25; Aqua Marine posted ₹10.7 lakh profit on ₹32.2 cr revenue.
Why this matters
Mukka is under liquidity pressure after a recent credit downgrade. The ₹47 crore warrant issue (7.3% of market cap) directly addresses that, while the two fish meal acquisitions expand capacity in a core segment. But one target is loss-making, and dilution is 6.7%: the trade-off balances a clearer balance sheet against near-term EPS drag.
What we're watching
- Conversion of warrants: 18-month window; early conversion would strengthen equity.
- Delta Marine turnaround timeline — at current losses it's a drag on margins.
- Whether working capital cycle eases with the fresh equity infusion.
The full read
Mukka Proteins is raising ₹47 crore via a preferential warrant issue at ₹23.50 each to 15 non-promoter investors. That's 7.3% of its market cap, with 6.7% potential dilution. Separately, it is buying 51% of Delta Marine for ₹11.1 crore and 51% of Aqua Marine for ₹15 crore. Delta Marine lost ₹19.7 lakh on ₹28.2 crore revenue in FY25; Aqua Marine earned ₹10.7 lakh on ₹32.2 crore. A calculated bet. The capital raise directly addresses the liquidity stress that triggered a CARE downgrade in May. The warrant structure gives cash now and pushes dilution 18 months out. For a ₹682 crore company, this is a material shift, offering balance sheet relief against future dilution and the challenge of turning around a loss-making target.
Questions answered
- Why is Mukka raising equity via warrants instead of a plain equity issue?
- Warrants provide immediate cash inflow of ₹47 crore while delaying dilution until conversion. If the share price rises above ₹23.50, existing holders face 6.7% dilution; if it stays below, the cash stays without full dilution.
- How material are the two acquisitions for Mukka's revenue?
- Delta Marine and Aqua Marine together contributed ₹60.4 crore revenue in FY25, about 4% of Mukka's trailing revenue. But their fish meal and fish oil businesses directly complement Mukka's core, adding production capacity.
- Is the ₹23.50 warrant price expensive given the stock's trajectory?
- The issue price is based on a registered valuer's report. Mukka's last traded price is not disclosed, but the company has a P/E of 13.1. At ₹23.50, the implied market cap would be roughly ₹705 crore, close to the current ₹682 crore.
- What does the credit downgrade mean for these plans?
- CARE downgraded Mukka in May 2026 on liquidity stress from a long working capital cycle. The warrant issue directly addresses that by injecting equity, which should improve debt-to-equity from 1.02 and ease lender confidence.
- How does the dilution compare to the acquisition value?
- Full warrant conversion would dilute equity by 6.7%, raising ₹47 crore. The acquisitions cost ₹26.1 crore for 51% stakes. So the net cash from the warrant issue after acquisitions is roughly ₹21 crore for working capital.
Mukka Proteins Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on MUKKA →- 12 Jun 2026 · 5:27 PM IST Mukka Proteins raises ₹47 cr via warrants, buys two fish meal firms for ₹26 cr
- 27d ago Mukka Proteins gets partial tax relief, ₹7.55 cr rate dispute remains
- 49d ago Mukka Proteins board to meet on June 12 for equity fundraise after credit downgrade
- 63d ago CARE Ratings cuts Mukka Proteins' credit rating on liquidity stress